0000950170-23-032913.txt : 20230713
0000950170-23-032913.hdr.sgml : 20230713
20230713212614
ACCESSION NUMBER: 0000950170-23-032913
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230711
FILED AS OF DATE: 20230713
DATE AS OF CHANGE: 20230713
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NSV Partners III GP LLC
CENTRAL INDEX KEY: 0001889601
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40928
FILM NUMBER: 231087872
BUSINESS ADDRESS:
STREET 1: 500 WEST PUTNAM AVE
STREET 2: SUITE 400
CITY: GREENWICH
STATE: CT
ZIP: 06830
BUSINESS PHONE: 2126885100
MAIL ADDRESS:
STREET 1: 500 WEST PUTNAM AVE
STREET 2: SUITE 400
CITY: GREENWICH
STATE: CT
ZIP: 06830
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NSV Partners III LP
CENTRAL INDEX KEY: 0001890004
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40928
FILM NUMBER: 231087873
BUSINESS ADDRESS:
STREET 1: 500 WEST PUTNAM AVE
STREET 2: SUITE 400
CITY: GREENWICH
STATE: CT
ZIP: 06830
BUSINESS PHONE: 2126885100
MAIL ADDRESS:
STREET 1: 500 WEST PUTNAM AVE
STREET 2: SUITE 400
CITY: GREENWICH
STATE: CT
ZIP: 06830
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ventyx Biosciences, Inc.
CENTRAL INDEX KEY: 0001851194
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 832996852
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 662 ENCINITAS BLVD., STE. 250
CITY: ENCINITAS
STATE: CA
ZIP: 92024
BUSINESS PHONE: (858) 945-2393
MAIL ADDRESS:
STREET 1: 662 ENCINITAS BLVD., STE. 250
CITY: ENCINITAS
STATE: CA
ZIP: 92024
4
1
ownership.xml
4
X0407
4
2023-07-11
0001851194
Ventyx Biosciences, Inc.
VTYX
0001890004
NSV Partners III LP
500 WEST PUTNAM AVENUE, SUITE 400
GREENWICH
CT
06830
false
false
true
false
0001889601
NSV Partners III GP LLC
500 WEST PUTNAM AVENUE, SUITE 400
GREENWICH
CT
06830
false
false
true
false
false
Common Stock
2023-07-11
4
S
false
28646
37.5414
D
8560141
D
Common Stock
2023-07-12
4
S
false
3275
37.6242
D
8556866
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by NSV Partners III, L.P. on February 24, 2023.
Represents the weighted average share price of an aggregate total of 28,646 shares sold in the price range of $37.50 to $37.675. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
NSV Partners III, L.P. is the general partner of NSV Investments I, L.P., NSV Investments III, L.P., and NSV Investments II, L.P.
Somasundaram Subramaniam is the majority member and managing member of NSV Partners III GP, LLC, and may be deemed to have voting and dispositive power over the shares owned by each entity of which NSV Partners III, L.P. is general partner. Mr. Subramaniam is the majority member and managing member NSV Partners II, LLC. Mr. Subramaniam is the majority member and managing member of New Science Ventures, LLC. Mr. Subramaniam disclaims beneficial ownership over the shares owned by each of the NSV Funds (as defined below), except to the extent of his pecuniary interest therein. Mr. Subramaniam is a director of the issuer and files separate reports under Section 16 of the Securities Exchange Act of 1934, as amended.
The shares beneficially owned by the reporting persons consist of: (i) 5,004,701 shares held by NSV Investments I, L.P., (ii) 978,835 shares held by NSV Investments III, L.P., (iii) 1,502,112 shares held by NSV Partners III, L.P., (iv) 434,423 shares held by New Science Ventures, LLC, (v) 408,520 shares held by NSV Partners II, LLC, and (vi) 232,180 shares held by NSV Investments II, L.P. (collectively, the "NSV Funds"). The NSV Funds disclaim beneficial ownership over the shares owned by them, except to the extent of their pecuniary interest therein.
Represents the weighted average share price of an aggregate total of 3,275 shares sold in the price range of $37.50 to $37.862. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
The shares beneficially owned by the reporting persons consist of: (i) 5,004,701 shares held by NSV Investments I, L.P., (ii) 978,835 shares held by NSV Investments III, L.P., (iii) 1,498,837 shares held by NSV Partners III, L.P., (iv) 434,423 shares held by New Science Ventures, LLC, (v) 408,520 shares held by NSV Partners II, LLC, and (vi) 232,180 shares held by NSV Investments II, L.P. The NSV Funds disclaim beneficial ownership over the shares owned by them, except to the extent of their pecuniary interest therein.
/s/ NSV Partners III, LP, By: Brenda Marex, Chief Financial Officer
2023-07-13
/s/ NSV Partners III GP, LLC, By: Brenda Marex, Chief Financial Officer
2023-07-13